|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lan T, Yuan K, Yan X, Xu L, Liao H, Hao X,
Wang J, Liu H, Chen X, Xie K, et al: LncRNA SNHG10 facilitates
hepatocarcinogenesis and metastasis by modulating its homolog
SCARNA13 via a positive feedback loop. Cancer Res. 79:3220–3234.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Q and Holst J: L-type amino acid
transport and cancer: Targeting the mTORC1 pathway to inhibit
neoplasia. Am J Cancer Res. 5:1281–1294. 2015.PubMed/NCBI
|
|
4
|
Kanai Y: Amino acid transporter LAT1
(SLC7A5) as a molecular target for cancer diagnosis and
therapeutics. Pharmacol Ther. 230:1079642022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaira K, Takahashi T, Murakami H, Shukuya
T, Kenmotsu H, Naito T, Oriuchi N, Kanai Y, Endo M, Kondo H, et al:
Relationship between LAT1 expression and response to platinum-based
chemotherapy in non-small cell lung cancer patients with
postoperative recurrence. Anticancer Res. 31:3775–3782.
2011.PubMed/NCBI
|
|
6
|
Zhao Y, Zhang J, Wang S, Jiang Q and Xu K:
Identification and validation of a nine-gene amino acid
metabolism-related risk signature in HCC. Front Cell Dev Biol.
9:7317902021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Q, Bailey CG, Ng C, Tiffen J, Thoeng
A, Minhas V, Lehman ML, Hendy SC, Buchanan G, Nelson CC, et al:
Androgen receptor and nutrient signaling pathways coordinate the
demand for increased amino acid transport during prostate cancer
progression. Cancer Res. 71:7525–7536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Q, Tiffen J, Bailey CG, Lehman ML,
Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M, et al:
Targeting amino acid transport in metastatic castration-resistant
prostate cancer: effects on cell cycle, cell growth, and tumor
development. J Natl Cancer Inst. 105:1463–1473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu P, Liu T and Hu Y: PI3K inhibitors for
cancer therapy: What has been achieved so far? Curr Med Chem.
16:916–930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shin E, Choi CM, Kim HR, Jang SJ and Park
YS: Immunohistochemical characterization of the mTOR pathway in
stage-I non-small-cell lung carcinoma. Lung Cancer. 89:13–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang BK, Moran AM, Bailey CG, Rasko JE,
Holst J and Wang Q: EGF-activated PI3K/Akt signalling coordinates
leucine uptake by regulating LAT3 expression in prostate cancer.
Cell Commun Signal. 17:832019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liver Cancer Study group of Japan, . The
general rules for the clinical and pathological study of primary
liver cancer. 3rd English edition. Tokyo: Kanehara & Co., Ltd;
2010
|
|
14
|
Ishikawa D, Shimada M, Utsunomiya T,
Morine Y, Imura S, Ikemoto T, Arakawa Y, Kanamoto M, Iwahashi S,
Saito Y, et al: Effect of Twist and Bmi1 on intraductal papillary
mucinous neoplasm of the pancreas. J Gastroenterol Hepatol.
29:2032–2037. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Namikawa M, Kakizaki S, Kaira K, Tojima H,
Yamazaki Y, Horiguchi N, Sato K, Oriuchi N, Tominaga H, Sunose Y,
et al: Expression of amino acid transporters (LAT1, ASCT2 and xCT)
as clinical significance in hepatocellular carcinoma. Hepatol Res.
45:1014–1022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmitz KJ, Wohlschlaeger J, Lang H,
Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR,
Schmid KW and Baba HA: Activation of the ERK and AKT signalling
pathway predicts poor prognosis in hepatocellular carcinoma and ERK
activation in cancer tissue is associated with hepatitis C virus
infection. J Hepatol. 48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rii J, Sakamoto S, Sugiura M, Kanesaka M,
Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, et al:
Functional analysis of LAT3 in prostate cancer: Its downstream
target and relationship with androgen receptor. Cancer Sci.
112:3871–3883. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu SM, Tang K, Meng L and Tang Y:
Suppression of amino acid transporter LAT3 expression on
proliferation of K562 cells. J Huazhong Univ Sci Technolog Med Sci.
33:632–635. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ritchie JW and Taylor PM: Tryptophan and
iodothyronine transport interactions in HepG2 human hepatoma cells.
Amino Acids. 38:1361–1367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang S, Chen X, Huang Z, Chen D, Yu B,
Chen H, Luo J, He J, Zheng P and Yu J: Leucine promotes
differentiation of porcine myoblasts through the protein kinase B
(Akt)/Forkhead box O1 signalling pathway. Br J Nutr. 119:727–733.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nanashima A, Morino S, Yamaguchi H, Tanaka
K, Shibasaki S, Tsuji T, Hidaka S, Sawai T, Yasutake T and Nakagoe
T: Modified CLIP using PIVKA-II for evaluating prognosis after
hepatectomy for hepatocellular carcinoma. Eur J Surg Oncol.
29:735–742. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okano N, Naruge D, Kawai K, Kobayashi T,
Nagashima F, Endou H and Furuse J: First-in-human phase I study of
JPH203, an L-type amino acid transporter 1 inhibitor, in patients
with advanced solid tumors. Invest New Drugs. 38:1495–1506. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Grkovic T, Font J, Bonham S,
Pouwer RH, Bailey CG, Moran AM, Ryan RM, Rasko JE, Jormakka M, et
al: Monoterpene glycoside ESK246 from Pittosporum targets
LAT3 amino acid transport and prostate cancer cell growth. ACS Chem
Biol. 9:1369–1376. 2014. View Article : Google Scholar : PubMed/NCBI
|
